Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.
Antonio D'AlessioClaudia Angela Maria FulgenziNaoshi NishidaMartin SchönleinJohann von FeldenKornelius SchulzeHenning WegeVincent E GaillardAnwaar SaeedBrooke WietharnHannah HildebrandLinda WuCelina AngThomas U MarronArndt WeinmannPeter R GalleDominic BettingerBertram BengschArndt VogelLorenz BalcarBernhard ScheinerPei-Chang LeeYi-Hsiang HuangSuneetha AmaraMahvish MuzaffarAbdul Rafeh NaqashAntonella CammarotaNicola PersoneniTiziana PressianiRohini SharmaMatthias PinterAlessio CortelliniMasatoshi KudoLorenza RimassaDavid J PinatoPublished in: Hepatology (Baltimore, Md.) (2022)
This study confirms reproducible safety and efficacy of AtezoBev in routine practice. Patients with CP-B reported similar tolerability compared with CP-A, warranting prospective evaluation of AtezoBev in this treatment-deprived population.